Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

116
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
116
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

113
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
113
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

158
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
158
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

151
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
151
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

159
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
159
Respiratory Assessment: Purpose and Indications01:19

Respiratory Assessment: Purpose and Indications

1.0K
Respiratory assessment is a cornerstone of nursing assessments, crucial for the early detection of patient deterioration. This evaluation transcends routine procedures, representing a critical skill nurses must master to ensure optimal patient care.
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating Novel Adipokines in Critically Ill Patients with and Without Sepsis.

Biomedicines·2026
Same author

Right ventricular strain assessed by two-dimensional speckle tracking echocardiography and mortality in acute respiratory distress syndrome: a systematic review and meta-analysis.

Acute and critical care·2026
Same author

The impact of colistin minimum inhibitory concentration on clinical failure and mortality: insights from the OVERCOME trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Temporal Aquaporin Expression Profiles in Immune Cell Subsets during Critical Illness.

Shock (Augusta, Ga.)·2026
Same author

Relative contribution of driving pressure and respiratory rate to mortality in ARDS depends on age.

American journal of respiratory and critical care medicine·2026
Same author

The Complement System in the Setting of Critical Illness-A Narrative Review.

Biomolecules·2026

Related Experiment Video

Updated: May 26, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.3K

FRAIL PARTICIPANTS IN RANDOMIZED CONTROLLED TRIALS OF ACUTE RESPIRATORY DISTRESS SYNDROME.

Theodora K Ntaidou1, Vassilis G Giannakoulis1, Eleni Papoutsi1

  • 1First Department of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Shock (Augusta, Ga.)
|February 24, 2025
PubMed
Summary
This summary is machine-generated.

Frailty is increasingly represented in acute respiratory distress syndrome (ARDS) clinical trials, but outcomes for frail patients have not improved. This vulnerable population requires consideration in future ARDS trial designs.

More Related Videos

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.7K
Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS
07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS

Published on: September 7, 2016

11.2K

Related Experiment Videos

Last Updated: May 26, 2025

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.3K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.7K
Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS
07:20

Lavage-induced Surfactant Depletion in Pigs As a Model of the Acute Respiratory Distress Syndrome ARDS

Published on: September 7, 2016

11.2K

Area of Science:

  • Critical Care Medicine
  • Clinical Trials
  • Geriatrics

Background:

  • Frailty is prevalent in intensive care units and linked to adverse outcomes.
  • Data on frail individuals in acute respiratory distress syndrome (ARDS) interventional trials are limited.
  • Temporal trends in frail patient representation and outcomes in ARDS trials are not well understood.

Purpose of the Study:

  • To analyze trends in the representation of frail participants in randomized controlled trials (RCTs) for ARDS.
  • To assess changes in outcomes for frail participants in ARDS trials over time.

Main Methods:

  • Secondary analysis of five ARDS Network and PETAL Network trials (2006-2019).
  • Participants categorized as frail or non-frail based on pre-hospitalization need for assistance.
  • Statistical analysis to evaluate temporal trends and associations with outcomes.

Main Results:

  • 19.3% of 3,630 ARDS participants were frail; their representation increased over time (P=0.001).
  • Mortality for frail participants remained high and stable (39.4%, P=0.403).
  • Frailty independently predicted 90-day mortality (OR 1.62) and was associated with fewer ventilator-free days and increased disability.

Conclusions:

  • Despite increased enrollment, frail patients in ARDS trials show no improvement in mortality.
  • A significant proportion of frail ARDS patients are under 65, highlighting a younger vulnerable group.
  • Future ARDS trial designs must account for the growing and persistently vulnerable population of frail individuals.